About Us
Blog
Documentation
Careers
Contact
Launch Marketplace
The Molecule Blog
All media:
IPNFT
Filter posts by
DeSci
Tech
Medicine
IPNFT
BioDAO
News
The DeSci Podcast
Feb 17, 2023
•
Esha Bora, Heinrich Tessendorf
HairDAO: Breaking the 'Cosmetic Condition' Barrier and Unlocking New Funding Possibilities with IP-NFTs
HairDAO, a BioDAO that is currently a part of the bio.xyz accelerator, had their first IP-NFT transaction. For $75k, HairDAO will gain access to the initial data from Dr. Ralf Paus’ lab Cutaneon. Then, based on the results, HairDAO may opt to test combinations of T3/T4 thyroid hormone at different dosages for an additional $50k.
Read More
Dec 21, 2022
•
Tyler Golato, Vincent Weisser
The Scientific Singularity: Our Vision for The Future of Research with IP-NFTs
The future of research is collaborative, digital, and highly autonomous. Patents today are not. We are building the intellectual property system that will help usher in this new era.
Read More
Dec 19, 2022
•
Clemens Ortlepp
Introducing the IP-NFT V2
In 2021, our team at Molecule published the first implementation of intellectual property NFTs (IP-NFTs). A solution that wraps intellectual property rights such as patents, datasets, or contractual agreements inside a non-fungible token, enabling easy transfer and collective ownership over such assets. Together with VitaDAO, we managed to demonstrate that this new asset class can be a viable investment instrument for biotech research.
Read More
Sep 13, 2022
•
Heinrich Tessendorf, Lutz Kummer
Novel rejuvenation therapy funded through an IP-NFT
We are pleased to announce that Molecule’s IP-NFT funding framework will facilitate critical preclinical work in Dr. Amit Sharma’s laboratory at the SRF Research Center to eliminate the accumulation of senescent cells in age-related diseases.
Read More
Aug 2, 2022
•
Heinrich Tessendorf
Molecule’s first IP-NFT for drug discovery R&D in the United States
Today we’re excited to announce Molecule’s IP-NFT funding paradigm has crossed the ocean to support age-related oral health research at the University of Washington in Seattle.
Read More
Jun 15, 2022
•
Heinrich Tessendorf, Lutz Kummer
Molecule’s IP-NFT is now facilitating Alzheimer´s research at the University of Oslo
We are delighted to share that the laboratory of Evandro Fang at the Akershus University Hospital and the University of Oslo became the third ever lab to fund their research project via Molecule’s IP-NFT framework - The discovery of novel mitophagy activators for Alzheimer´s disease and healthy longevity.
Read More
Apr 14, 2022
•
Paul Kohlhaas, Andrew Steinwold
Paul Kohlhaas - DeSci: The Future of Decentralized Science - Zima Red Podcast
Paul Kohlhaas visited the Podcast of Andrew Steinwald, and spoke about his path into the pharmaceutical space and web3. He shares his experiences in biohacking, the pharma industry, the drug development process and how web3 could play a crucial role in making drug development more efficient, fair and transparent. This is achieved through BioDAOs an open source approach of pharmaceutical early stage research and leveraging the traits of NFTs through and a new standard, the IP-NFT. Molecule is a company that is virtualizing and decentralizing how drug development works. They do this by attaching data and IP rights to non-fungible tokens (NFT's) and then bringing the core IP into web3. This makes the intellectual property liquid, which is very hard to achieve in biotech today, and also enables price discovery around IP. Molecule has created a curation market where people can trade and discover therapeutics for drugs. Molecule has also started building biotech DAOs, which are research collectives that are comprised of patients, investors, and researchers in a specific therapeutic area. The mission is to democratize access to medicine by empowering researchers and patients to become co-owners of the IP and data associated with a new therapeutic. Paul describes how the company's IP-NFTs work to store data associated with a new therapeutic and how they can be used to fractionalize ownership of the IP. He also walks through the company's roadmap and explains how they plan to decentralize ownership of the data and IP associated with a new therapeutic. Paul discusses the origins of VitaDAO and IP-NFT, the process of setting up a DAO, and the long-term vision for a DAO-based ecosystem for pharmaceutical research and development.The grand vision for the projects is to develop a drug that is enabled and discovered through the process and reaches patients in a eight to ten year timeframe. He also discusses the potential for IP-NFTs to be used to fractionalize the ownership of IP and allow patients to contribute funding to research."
Read More
Aug 19, 2021
•
Tyler Golato
IP-NFTs for Researchers: A New Biomedical Funding Paradigm
TL;DR: This week, the first university biomedical intellectual property (IP) and research project was funded as an NFT (non-fungible token), enabled by a pioneering innovation at Molecule. The IP-NFT enables new fundraising and collaboration strategies for researchers by combining legal and technical frameworks with NFT technology. Early-stage research can be financed without endless grant applications, creating a startup and raising VC or needing to file a patent.
Read More
Aug 13, 2021
•
Clemens Ortlepp
Announcing the first biopharma IP-NFT Transaction
Throughout the past 2 weeks VitaDAO Token Holders got to vote on the proposal “VDP-5 Scheibye-Knudsen Lab Funding” to fund longevity at the Scheibye-Knudsen Lab in Copenhagen. The voting passed with 2.1M token votes and 88% of votes supporting the proposition. With the proposal having been approved by the DAO members, the lab in Copenhagen will receive $250.000 for the first research phase of the project over a period of 12 months. After successful completion and review of Phase 1 by the DAO, another $250.000 for an additional 12 months of research could be handed out to the lab. As part of this deal, VitaDAO will fully own the intellectual property (IP) resulting from the research project. The first biopharma IP that will be owned and managed by a DAO. Ownership and access management to the IP will be handled via Molecule’s novel IPNFT framework. The infrastructure is utilizing Ethereum ERC721, Arweave and Nevermined.
Read More
Aug 6, 2021
•
Clemens Ortlepp
Molecule’s Biopharma IP-NFTs - A Technical Description
Globally, early-stage biopharma research suffers from chronic underfunding, leading to discontinued research in the early stages of the pharma development cycle. This is happening so regularly that academia has coined the phase of research up until clinical trials the “Valley of Death”. Researchers struggle to acquire funding due to three distinct reasons:Lack of visibility and connection to relevant investors: Researchers struggle to connect and acquire funding from private investorsLegal complexity of IP deals: Deals such as licence agreements surrounding pre-patent and patent IP are complex and often need legal supportDifficulty of determining the value of early-stage biopharma assets: Both funders and researchers have trouble assessing the value of early-stage research.NFTs have created an unprecedented revolution in the creative space, rethinking copyright, royalties and IP. We believe it will also be instrumental in solving the above-stated problems. In this article, we are going to focus on the first technical implementation of a biopharma IPNFT. It builds on many concepts other influential thinkers in the Web3 space have conjured in the past. For example, if you are interested in how general IP can be combined with NFTs, have a look at Trent McConaghy 3 part series on building IP NFTs with ERC721.
Read More
Jul 11, 2021
•
Paul Kolhaas
An Open Bazaar for Drug Development: Molecule Protocol
Imagine a world where patients directly fund researchers developing the next therapeutic breakthrough they need. One where drug development is collaborative, open, and decentralized — an open bazaar anyone with the right intentions can join. A system that could radically increase the diversity of treatments, and lower costs and time to market.
Read More
Join us, contribute ideas, and stay up to date
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our
Privacy Policy
for more information.
Deny
Accept
Privacy Preferences
Essential cookies
Required
Marketing cookies
Essential
Personalization cookies
Essential
Analytics cookies
Essential
Reject all cookies
Allow all cookies
Save preferences